IT is devastating to hear that Kadcyla – a crucial life-extending treatment for women with incurable secondary breast cancer – faces being withdrawn from the NHS, following the failure of NICE and the drug’s manufacturer, Roche, to reach an agreement. Kadcyla can offer patients precious extra months – even years – of good quality time with their loved ones, with fewer side effects than other treatments.